July 17, 2025 | Aclymate, Carbon Emissions, Carbon footprint, Hybrid Events, Hybrid meetings, Impetus Digital, Pharma meetings, Sustainability, carbon neutral, green pharma, pharma vvents, reduce carbon, sustainable pharma
Impetus Digital was promoted to the Aclymate Silver Tier for their efforts in crafting carbon-neutral virtual and live meetings for life science companies.

A year after Impetus Digital first calculated and offset all of our home office-related emissions, we’re excited to announce that we have now implemented Phase 2 of our journey toward carbon neutrality. As of January 2024, all of the carbon emissions associated with Impetus Digital staff attending hybrid meetings live (i.e., flights, ground transportation for local meetings, and accommodation) have been–and will continue to be–offset. This means that–while we still encourage clients to go fully virtual to cut down on their meeting-associated emissions almost entirely–those opting for a hybrid event can still feel good knowing that any Impetus support staff attending the meeting in person is not contributing to the carbon footprint of the event.
In fact, we were recently promoted to the Aclymate Silver Tier for our efforts to date. Plus, we continue to be platinum-certified by the Green Business Benchmark (GBB), demonstrating our commitment to sustainable practices!
Phase 3 and beyond will involve calculating and offsetting the emissions associated with the actual meeting venues, any Impetus business trips for reasons other than attending live client meetings and events (e.g., conference attendance), and the small but non-negligible emissions associated with our online portals. Stay tuned for more updates!
This content was provided by Impetus Digital
Company Details
Latest Content from Impetus Digital
Jim Lefevere, Director of Global Marketing Services at Roche, discusses the changes in digital marketing strategies, workflow, team dynamics, and required skill sets among Pharma teams brought on by COVID-19….
Max Newlon, President of Brain Co., discusses everything from meditation practices and behavioral science to the use of technology in assessing and treating mental health conditions. He also delves into…
Andreas Weber, Group CEO, EvidentIQ, discusses hybrid vs. fully decentralized trials, the use of real-world evidence (RWE) in clinical trials, and how an end-to-end eClinical solution can help meet increasing…
Read the full article here or on the Green Business Bureau blog for more details.
Dr. Justin Barad, CEO and Founder of Osso VR, explores how VR and gamification are revolutionizing surgical training by providing accurate quantitative assessments and analytics before performing on a patient….
Joshua Yang, Co-founder & CEO of Glyphic Biotechnologies and Co-founder of NephroSant, dives into next-generation protein sequencing for biomedical research and clinical medicine, his journey from academia to entrepreneurship, and…
Toronto, ON, November 25, 2021– After a lengthy submission and voting process and amongst fierce competition, Impetus Digital has been selected as a winner of Canada’s Most Admired Corporate Cultures…
Christina Stokes, Founder of CyberRhythms Consulting and Writer at CyberSolace.io, explores cybersecurity in healthcare, the importance of keeping patient data safe (and the consequences of a breach), and current/future challenges…
Michael Duke, Principal Healthcare Consultant at Baker Tilly US, discusses the importance of data and analytics for internal audits, organizational risk reduction, workflow automation, and to drive value in healthcare….
Hector Bremner, CEO of Avricore Health, discusses the benefits of comprehensive point-of-care testing for patient monitoring, real-world studies, and decentralized clinical trials; how his company is working on becoming the…


